New combo therapy shows promise for hard-to-treat colorectal cancer in early trial
NCT ID NCT02512172
First seen Dec 10, 2025 · Last updated May 14, 2026 · Updated 23 times
Summary
This early-phase study tested whether adding two drugs (romidepsin and 5-azacitidine) to an immunotherapy (MK-3475) could help people with a specific type of advanced colorectal cancer called microsatellite stable (MSS). The study included 27 adults whose cancer had already spread and who had tried at least one prior treatment. The main goals were to check safety and see if the combination could increase immune cells in tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, 21205, United States
Conditions
Explore the condition pages connected to this study.